The Sustainable Development Goals (SDGs), adopted at the UN Sustainable Development
Summit held in September 2015, comprise 17 goals and 169 targets to create a future where no one is left
behind and are global efforts to be accomplished by 2030.
In response to the diverse and changing social expectations and demands, the Sumitomo
Pharma Group has identified Material Issues based on its belief that it is important to realize both
contribution to social sustainability and its own sustained growth through the creation of value that only it
can deliver by utilizing the Group’s capital (strengths) and also the development goals of the SDGs.
Going forward, the Sumitomo Pharma Group will continue to contribute to the
realization of a sustainable society by addressing the issues facing society.
SDGs to which the Sumitomo Pharma Group contributes
While concentrating our efforts primarily on Goal 3, which is directly related to
Sumitomo Pharma’s Mission and where we can best utilize our strengths, we are also actively working on
Goal 8, 10, 12, 13, 16, and 17.
The Sumitomo Pharma Group’s Top Priority: Sustainable Development Goals and
Main Targets
Goals
Targets
Initiatives of the pharmaceutical business (psychiatry & neurology, oncology etc.), the
Regenerative Medicine/Cell Therapy Business and the Frontier Business (3.4)
Addressing product safety and adverse reactions (3.4)
Providing and collecting product information (healthcare professionals) (3.4)
Initiatives to improve medicine-related literacy (3.4)
Operation of information websites for healthcare professionals and for patients and general
public (3.4)
Initiatives aimed at appropriate use of antibiotics and countermeasures to antimicrobial
resistance (AMR) (3.3)
Participation in GHIT Fund to develop medicines for malaria and other infectious diseases (3.3)
Health and productivity management (welfare of employees and promoting mental health) (3.8)
Promotion of Work Style Innovation aimed at more sophisticated work styles and a virtuous cycle in
work-life balance (8.5)
CSR procurement (8.7)
Supporting active participation by people with disabilities through appropriate placement (8.5)
Health and productivity management (welfare of employees and promoting mental health) (8.5)
Supporting active participation by people with disabilities through appropriate placement (10.2)
Supporting independence and social reintegration of people with disabilities (10.2)
CSR procurement (10.2, 10.3)
Support for developing countries through company cafeterias (10.2)
Maintenance and improvement of recycling rate for waste (12.4, 12.5)
Risk mitigation of environmental accidents (12.4)
Initiatives to reduce environmental impact throughout products' lifecycles (12.4, 12.5)
Stable product supply and quality assurance (12.6)
Risk mitigation of natural disasters (12.6)
Responding to TCFD (13.1)
Implementing planned investment in carbon neutral equipment(13.1)
Replace company vehicles with hybrid or electric vehicles (13.1)
Collaboration with Sumitomo Chemical group companies and Sumitomo Pharma's subsidiaries (SBT), and
collaboration with supply chains (Scope3) (13.1)
Effective use of energy via “Decokatsu” initiative and other energy saving actions (13.1)
Utilization of solar power generating systems (13.1)
Purchase of renewable energy-derived electricity (13.1)
Purchase of Non-Fossil Certificates (13.1)
Initiatives to reduce environmental impact throughout products' lifecycles (13.1)
Enhancement of corporate governance (16.5)
Pursuing compliance (16.1, 16.5)
CSR procurement (16.1, 16.2, 16.5)
Partnership activities for sustainable development（17.7）
Industry-academia-government collaborative R&D (academic institutions, startup companies, AMED,
GHIT Fund, etc.)
JPMA (Japan Pharmaceutical Manufacturers Association)
CDP
TABLE FOR TWO, etc.
